Eli Lilly and Incyte have another rival in the rear-view mirror for Olumiant in alopecia areata after Pfizer reported that its ritlecitinib improved scalp hair regrowth in a late-stage trial.

Given as a once-daily tablet, Litfulo (ritlecitinib) has been recommended by cost-effectiveness agency NICE for use in people aged 12 and over. The decision comes a few months after the first drug ...

The daily pill, called ritlecitinib or Litfulo, was green-lit for prescription on the NHS in February and is thought to grow hair back in up to 40% of people. According to the National Institute ...

The daily pill, called ritlecitinib or litfulo, could help up to 14,000 people in England, says the National Institute for Health and Care Excellence (NICE). Scotland is currently considering ...